H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Axsome Therapeutics to $200 from $210 and keeps a Buy rating on the shares. The company’s transition to a third-party logistics model this year will have some impact on revenue growth in Q1, the analyst tells investors in a research note. The firm continues to expect Axsome to potentially achieve cash flow break-even and sustainable profitability in 2024.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- Axsome selloff on SVB exposure should be bought, says Mizuho
- Axsome Therapeutics says ‘material cash deposits’ with SVB, Citibank
- Axsome Therapeutics price target lowered to $84 from $86 at Mizuho
- Axsome Therapeutics price target lowered to $90 from $105 at Guggenheim
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update